Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP

Blood (2021) 137 (6): 733–742.

https://doi.org/10.1182/blood.2020008021

Published: 2021

Includes: Supplemental data

Journal Articles

Patterns of Renal Recovery and Toxicity with Novel Agent-Based Induction Triplets in Newly Diagnosed Multiple Myeloma - an Analysis of Two Prospective Studies By the German DSMM Myeloma Study Group

Blood (2019) 134 (Supplement_1): 1840.

https://doi.org/10.1182/blood-2019-125235

Published: 2019

Journal Articles

Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect ® MM Registry

Lynne I. Wagner, PhD, Kathleen Toomey, MD, Sikander Ailawadhi, MD, Sundar Jagannath, Cristina Gasparetto, MD, Brian G.M. Durie, MD, Mohit Narang, MD, Robert M. Rifkin, MD, Howard R. Terebelo, DO, James L. Omel, MD, James W. Hardin, PhD, Hans C. Lee, MD, Shankar Srinivasan, PhD MBA, Liang Liu, MS, Mazaher Dhalla, PharmD, Donna Catamero, ANP-BC, OCN, CCRC, Rafat Abonour, MD

Blood (2019) 134 (Supplement_1): 1843.

https://doi.org/10.1182/blood-2019-126143

Published: 2019

Journal Articles

Comparative Effectiveness of Triplets Containing Bortezomib (V), Carfilzomib (K), or Ixazomib (I) Combined with a Lenalidomide and Dexamethasone Backbone (Rd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care in the United States (US)

Ajai Chari, MD, Dorothy Romanus, RPh, PhD, Aditya Raju, Lauren Cain, Marlo Blazer, PharmD, Eileen Farrelly, Dawn Marie Stull, Sikander Ailawadhi, MD

Blood (2019) 134 (Supplement_1): 1827.

https://doi.org/10.1182/blood-2019-121658

Published: 2019

Journal Articles

Retrospective Analysis of the Efficacy of Triplet Therapy, Including Lenalidomide, in Newly Diagnosed Multiple Myeloma Patients Who Obtained Responses Less Than VGPR after Rd Therapy

Naoki Takezako, MD PhD, Naoya Kaneko, MD, Airi Hamano, Ph, Kenichi Ito, MD, Naohiro Sekiguchi, MD, Satoshi Noto, MD, Takanori Teshima, MD

Blood (2019) 134 (Supplement_1): 5595.

https://doi.org/10.1182/blood-2019-131617

Published: 2019

Journal Articles

Outcomes of Lenalidomide Retreatment with Novel Triplet Regimens in Multiple Myeloma Patients Progressing on Lenalidomide-Based Maintenance Therapy: A Single Center Retrospective Analysis

Chutima Kunacheewa, MD, Lei Feng, MS, Elisabet E. Manasanch, MD, Qaiser Bashir, MBBS, Krina K. Patel, MDMSc, Rohtesh S. Mehta, MD, Gregory P. Kaufman, MD, Swaminathan P. Iyer, MD, Sheeba K. Thomas, MD, Donna M. Weber, MD, Robert Z. Orlowski, MD, PhD, Muzaffar H. Qazilbash, MD, Hans C. Lee, MD

Blood (2019) 134 (Supplement_1): 3198.

https://doi.org/10.1182/blood-2019-130537

Published: 2019

Journal Articles

Evolving Treatment Trends in Relapsed/Refractory Multiple Myeloma (RRMM) in Europe from 2016 to 2018: Analysis of a Multi-National Survey

Maximilian Merz, Isabelle Vande Broek, MD PhD, Manuel Pérez, Dr., Brigitte Kolb, MD, Argiris Symeonidis, MD PhD, Emmanouil Nikolousis, Athanasios Zomas, Francisco Gonzalez, Lenka Kellermann, BS, MBA, Hartmut Goldschmidt

Blood (2019) 134 (Supplement_1): 3115.

https://doi.org/10.1182/blood-2019-122706

Published: 2019

Journal Articles

In Vivo Kinetics of Early, Hypomethylating Agent-Induced Methylome and Transcriptome Changes in Primary AML Blasts: Random or Specific?

Gabriele Greve, Geoffroy Andrieux, Pascal Schlosser, Nadja Blagitko-Dorfs, Hans-Walter Lindemann, MD, Michael Heuser, MD, Andreas Neubauer, Jürgen Krauter, MD, Helmut R. Salih, MD, Gerhard Heil, Carsten Schwänen, Carsten Müller-Tidow, Arnold Ganser, MD, Hartmut Döhner, MD, Dietmar Pfeifer, Björn Hackanson, Olga Grishina, Melanie Boerries, Michael Lübbert

Blood (2018) 132 (Supplement 1): 3892.

https://doi.org/10.1182/blood-2018-99-118762

Published: 2018

Journal Articles

Fixed Dose Carfilzomib Triplets in Lenalidomide Refractory Myeloma

David Simpson, MBChB, FRACP, FRCPA, Henry Chan, MBChB

Blood (2018) 132 (Supplement 1): 3306.

https://doi.org/10.1182/blood-2018-99-110891

Published: 2018

Journal Articles

Phase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in Relapsed/Refractory Lymphoma Patients through Fixed-Dose Combination and Synthetic Lethality

Blood (2018) 132 (Supplement 1): 5384.

https://doi.org/10.1182/blood-2018-99-112944

Published: 2018

Journal Articles

Evolving Areas of Consensus and Disagreement Among Experts in Treatment of Patients with Multiple Myeloma (MM)

Kristen M Rosenthal, PhD, Irene M. Ghobrial, MD, Carol Ann Huff, MD, Sagar Lonial, MD, Noopur Raje, MD, Kevin L Obholz, PhD, Shaji K. Kumar, MD

Blood (2018) 132 (Supplement 1): 5664.

https://doi.org/10.1182/blood-2018-99-118941

Published: 2018

Journal Articles

Thalidomide Does Not Compromise Mobilization with Cytokine Alone in Multiple Myeloma after Triplet Induction Regimen

Matevz Skerget, MD PhD, Matjaz Sever, MD PhD, Barbara Skopec, MD PhD

Blood (2018) 132 (Supplement 1): 5691.

https://doi.org/10.1182/blood-2018-99-116124

Published: 2018

Journal Articles

Estimating the Effect of Individual Agents in the Treatment of Relapsed, Refractory Multiple Myeloma (RRMM)

Neil Hawkins, Karthik Ramasamy, Sujith Dhanasiri

Blood (2018) 132 (Supplement 1): 2013.

https://doi.org/10.1182/blood-2018-99-111804

Published: 2018

Journal Articles

A Quadruplet Regimen Comprising Carfilzomib, Cyclophosphamide, Lenalidomide, Dexamethasone (KCRD) Vs an Immunomodulatory Agent Containing Triplet (CTD/CRD) Induction Therapy Prior to Autologous Stem Cell Transplant: Results of the Myeloma XI Study

Blood (2018) 132 (Supplement 1): 302.

https://doi.org/10.1182/blood-2018-99-114956

Published: 2018

Journal Articles

Treatment of Relapsed and Refractory Multiple Myeloma with Fully Oral Triplet IRD (ixazomib, lenalidomide and dexamethasone) Is Safe and with Significant Therapeutic Outcomes

Blood (2018) 132 (Supplement 1): 1959.

https://doi.org/10.1182/blood-2018-99-112046

Published: 2018

Journal Articles

A new triple threat to CLL

Benjamin L. Lampson, Matthew S. Davids

Blood (2018) 132 (15): 1547–1548.

https://doi.org/10.1182/blood-2018-08-870808

Published: 2018

Journal Articles

Magarotto V, Bringhen S, Offidani M, et al. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Blood. 2016;127(9):1102-1108.

Blood (2018) 131 (13): 1495.

https://doi.org/10.1182/blood-2018-02-832048

Published: 2018

Journal Articles

Real-World Treatment Outcomes in Patients with Newly Diagnosed Multiple Myeloma Treated with Triplet Therapy without Stem Cell Transplant: An Enhanced Electronic Health Records Database

Ajai Chari, MD, Brian Ung, PharmD, Safiya Abouzaid, MPH, PharmD, Quanhong Ni, MS, Kejal Parikh, BSPharm, MS, Amit Agarwal, MD PhD

Blood (2017) 130 (Supplement 1): 2190.

https://doi.org/10.1182/blood.V130.Suppl_1.2190.2190

Published: 2017

Journal Articles

Computational Modeling of Protein Networks Predicts Treatment Outcomes in Multiple Myeloma (MM)

Leylah M. Drusbosky, PhD, Hemant S. Murthy, MD, Helen L. Leather, Himanshu Grover, MS, Yugandhara Narvekar, MS, Pallavi Kumari, MS, Sirisha Narayanabhatia, MS, Priyanka Bhowmick, MS, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Qing Zhang, PhD, Saad Z Usmani, MD, Christopher R. Cogle, MD

Blood (2017) 130 (Supplement 1): 592.

https://doi.org/10.1182/blood.V130.Suppl_1.592.592

Published: 2017

Journal Articles

Tourmaline US-MM6, an Open-Label, Single-Arm, Multicenter Study Evaluating the Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) in Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Switching from a Bortezomib-Based Triplet Induction Regimen

Robert M Rifkin, MD, Ralph V. Boccia, MD, Suman Kambhampati, MD, Joshua R Richter, MD, Saad Z Usmani, MD, Jack Aiello, EE, MS, BS, Brittany Sickler, BA, BS, Magdalena Schoeneich, MBA, MS, Bingxia Wang, PhD, Susan Zelt, PhD, Presley Whidden, MS, Lawrence E Dollar, PharmD, MS, Liviu Niculescu, MD, Stephen J Noga, MD

Blood (2017) 130 (Supplement 1): 5407.

https://doi.org/10.1182/blood.V130.Suppl_1.5407.5407

Published: 2017

NARROW

A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP

Patterns of Renal Recovery and Toxicity with Novel Agent-Based Induction Triplets in Newly Diagnosed Multiple Myeloma - an Analysis of Two Prospective Studies By the German DSMM Myeloma Study Group

Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect ® MM Registry

Comparative Effectiveness of Triplets Containing Bortezomib (V), Carfilzomib (K), or Ixazomib (I) Combined with a Lenalidomide and Dexamethasone Backbone (Rd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care in the United States (US)

Retrospective Analysis of the Efficacy of Triplet Therapy, Including Lenalidomide, in Newly Diagnosed Multiple Myeloma Patients Who Obtained Responses Less Than VGPR after Rd Therapy

Outcomes of Lenalidomide Retreatment with Novel Triplet Regimens in Multiple Myeloma Patients Progressing on Lenalidomide-Based Maintenance Therapy: A Single Center Retrospective Analysis

Evolving Treatment Trends in Relapsed/Refractory Multiple Myeloma (RRMM) in Europe from 2016 to 2018: Analysis of a Multi-National Survey

In Vivo Kinetics of Early, Hypomethylating Agent-Induced Methylome and Transcriptome Changes in Primary AML Blasts: Random or Specific?

Fixed Dose Carfilzomib Triplets in Lenalidomide Refractory Myeloma

Phase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in Relapsed/Refractory Lymphoma Patients through Fixed-Dose Combination and Synthetic Lethality

Evolving Areas of Consensus and Disagreement Among Experts in Treatment of Patients with Multiple Myeloma (MM)

Thalidomide Does Not Compromise Mobilization with Cytokine Alone in Multiple Myeloma after Triplet Induction Regimen

Estimating the Effect of Individual Agents in the Treatment of Relapsed, Refractory Multiple Myeloma (RRMM)

A Quadruplet Regimen Comprising Carfilzomib, Cyclophosphamide, Lenalidomide, Dexamethasone (KCRD) Vs an Immunomodulatory Agent Containing Triplet (CTD/CRD) Induction Therapy Prior to Autologous Stem Cell Transplant: Results of the Myeloma XI Study

Treatment of Relapsed and Refractory Multiple Myeloma with Fully Oral Triplet IRD (ixazomib, lenalidomide and dexamethasone) Is Safe and with Significant Therapeutic Outcomes

A new triple threat to CLL

Magarotto V, Bringhen S, Offidani M, et al. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Blood. 2016;127(9):1102-1108.

Real-World Treatment Outcomes in Patients with Newly Diagnosed Multiple Myeloma Treated with Triplet Therapy without Stem Cell Transplant: An Enhanced Electronic Health Records Database

Computational Modeling of Protein Networks Predicts Treatment Outcomes in Multiple Myeloma (MM)

Tourmaline US-MM6, an Open-Label, Single-Arm, Multicenter Study Evaluating the Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) in Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Switching from a Bortezomib-Based Triplet Induction Regimen

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only